Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × necitumumab × 1 year × Clear all

Phase

Status

Sponsor Class

OTHER 1 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 534 Carboplatin 340 Paclitaxel 253 Cisplatin 245 Gemcitabine 219 Nivolumab 178 Pemetrexed 174 Docetaxel 171 Bevacizumab 169 Injections 142 Cyclophosphamide 130 atezolizumab 128 Capecitabine 118 Dexamethasone 115 Oxaliplatin 114 Fluorouracil 112 durvalumab 103 130-nm albumin-bound paclitaxel 97 Fulvestrant 96 Rituximab 89 fludarabine 87 venetoclax 86 Cetuximab 83 Leucovorin 82 Lenalidomide 82 Prednisone 79 Azacitidine 75 enzalutamide 71 tislelizumab 69 Trastuzumab 66

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00981058 2025-06-18

SQUIRE

Eli Lilly and Company

Phase 3 Completed

1,093 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡